State of the Union: The outgoing agency head had angered pharma companies, pro-life Republicans, and vaping lobbyists. The post FDA Commissioner Makary Resigns Amid Controversy appeared first on The American Conservative .
The head of the Food and Drug Administration (FDA), Marty Makary, resigned Tuesday after leading the agency for just 13 months. Makary’s tenure at the FDA was marked by significant controversy, as he angered a number of political constituencies. Makary was elevated to head the FDA by President Donald Trump as part of the administration’s embrace of the Make America Healthy Again movement, represented by Health Secretary Robert F. Kennedy Jr. His time at the FDA saw a significant exodus of agency officials and employees, which created turmoil in the agency’s drug review program and frustrated pharmaceutical companies waiting for regulatory approval for their products. He also angered pro-life Republicans, who accused him of…Open
Marty Makary's departure from the Food and Drug Administration may remove one of the Trump administration's lightning rods for controversy. - But it won't solve the organizational upheaval and political jockeying that marked much of his 13-month tenure. Why it matters: There's lots of uncertainty around how the Senate will find the bandwidth to confirm another FDA commissioner while it considers President Trump's nominees for Centers for Disease Control and Prevention director and surgeon general . - The FDA itself is also facing other key internal vacancies, including for directors of the centers overseeing drugs and biologics. - And there are questions about whether a successor will continue efforts to streamline clinical trials and…
Food and Drug Administration (FDA) Commissioner Marty Makary will announce his resignation on Tuesday, according to multiple outlets, amid mounting reports of President Trump's growing dissatisfaction with the physician’s tenure. Politico Pro was first to report on Tuesday that Makary is resigning from his role, set to be replaced by Kyle Diamantas, who will serve as acting director. A source [...]
The Food and Drug Administration was supposed to be the dull and predictable part of President Trump's health bureaucracy. - Instead, it's become the soap opera whose cliffhangers leave entire industries in suspense — most recently Friday's drama over reports that commissioner Marty Makary was about to be booted out. Why it matters: The FDA regulates about one-fifth of the U.S. economy, so organizational disarray , surprise policy moves and political interference can cause real disruption. State of play: The Johns Hopkins physician and researcher appeared to have been spared late last week after multiple outlets reported that President Trump had authorized his firing. - Under Makary, there's been considerable drama around abortion…
On the Feb. 16, 2026 edition of Rob Schmitt Tonight, Rob Schmitt is joined by guests for analysis and commentary on the day’s news and events. Guests include Jack Posobiec, Matt Schlapp, Rep. Nancy Mace, Kyle Diamantas and Rep. Chip Roy. Full episodes of NEWSMAX TV primetime shows (for International audiences only) are dubbed into foreign languages for our viewers abroad. For US viewers, you can watch NEWSMAX TV live or on-demand at http://NewsmaxPlus.com
PULSE POINTSWHAT HAPPENED: A major shakeup in leadership at the Department of Health and Human Services (HHS) is underway, with top aides departing from their current roles to other positions as the agency looks to amplify its Make America Healthy Again (MAHA) agenda.WHO WAS INVOLVED: HHS Deputy Secretary Jim O’Neill, General Counsel Mike Stuart, HHS […] The post RFK Jr. Overhauls HHS Leadership. appeared first on The National Pulse .
PULSE POINTS WHAT HAPPENED: A major shakeup in leadership at the Department of Health and Human Services (HHS) is underway, with top aides departing from their current roles to other positions as the agency looks to amplify its Make America Healthy Again (MAHA) agenda. WHO WAS INVOLVED: HHS Deputy Secretary Jim O’Neill, General Counsel Mike Stuart, HHS Secretary Robert F. Kennedy Jr., and Chris Klomp. WHEN & WHERE: February 13, 2026, at the Department of Health and Human Services. KEY QUOTE: “They are being offered jobs within the administration but will not be remaining in their current positions,” said a source familiar with the personnel changes. IMPACT: The changes reportedly form part of efforts to strengthen the management…Open
Two senior Trump administration health officials — including one who was running the Centers of Disease Control and Prevention — are leaving their posts as part of a staff shakeup by Health Secretary Robert F. Kennedy Jr. ahead of the midterm elections, two sources confirmed to Axios. Why it matters: The departures of deputy health secretary Jim O'Neill and general counsel Mike Stuart coincide with Kennedy's public emphasis on top administration priorities like cleaning up the food supply and lowering drug prices. - O'Neill was not only the second-ranking official at the Department of Health and Human Services, but also the acting director of the CDC. Driving the news: The staff shuffle will effectively make the current Medicare…
